| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proteomics and Protein Markers |
1 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
2 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
aAddress correspondence to this author at: Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 60 Murray St., Box 32, Rm. L6-206, Toronto, Ontario, Canada M5G 1X5. Fax 416-619-5521; e-mail ediamandis{at}mtsinai.on.ca.
Background: Kallikreins (KLKs) are a group of 15 secreted serine proteases. Some KLKs are established or candidate cancer biomarkers, but for most the physiological function is unknown. We characterized the protein and mRNA abundance patterns of all 15 KLKs in multiple panels of human tissues and biological fluids.
Methods: We used sensitive and specific sandwich-type ELISAs for each KLK. Reverse transcription PCR was used for transcript amplification. Multiple panels of human tissue extracts (adult and fetal) were tested, along with various biological fluids.
Results: Quantitative protein expression data on 7 sets of adult and 3 sets of fetal tissues were collected for all 15 KLKs. KLKs were also quantified in the following biological fluids: seminal plasma, breast milk, follicular fluid, breast cyst fluid, breast cancer cytosol, amniotic fluid, ovarian cancer ascites, cerebrospinal fluid, cervicovaginal fluid, and urine. The data were used to generate heat maps of KLK concentrations in tissues and fluids and categorize KLK abundance as highly restricted (KLK2 and KLK3 in prostate), restricted (KLK5 in skin, salivary gland, breast, and esophagus; KLK6 in brain and central nervous system; KLK7 in esophagus, heart, liver, and skin; KLK8 in breast, esophagus, skin, and tonsil; KLK13 in esophagus and tonsil), or wide (KLKs 1, 4, 9, 10, 11, 12, 14, and 15).
Conclusions: Quantitative KLK concentrations in tissues and fluids aid in the elucidation of KLK function, and coexpression patterns provide clues for KLK participation in proteolytic cascades.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  L. E. Lamb, B. S. Knudsen, and C. K. Miranti E-cadherin-mediated survival of androgen-receptor-expressing secretory prostate epithelial cells derived from a stratified in vitro differentiation model J. Cell Sci., January 15, 2010; 123(2): 266 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Planque, V. Kulasingam, C. R. Smith, K. Reckamp, L. Goodglick, and E. P. Diamandis Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines Mol. Cell. Proteomics, December 1, 2009; 8(12): 2746 - 2758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D Mulder, J. A Heijst, C. Mulder, F. Martens, C E. Hack, P. Scheltens, M. A Blankenstein, and R. Veerhuis CSF levels of PSA and PSA-ACT complexes in Alzheimer's disease Ann Clin Biochem, November 1, 2009; 46(6): 477 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. STROJNIK, R. KAVALAR, I. ZAJC, E. P. DIAMANDIS, K. OIKONOMOPOULOU, and T. T. LAH Prognostic Impact of CD68 and Kallikrein 6 in Human Glioma Anticancer Res, August 1, 2009; 29(8): 3269 - 3279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pampalakis, E. Prosnikli, T. Agalioti, A. Vlahou, V. Zoumpourlis, and G. Sotiropoulou A Tumor-Protective Role for Human Kallikrein-Related Peptidase 6 in Breast Cancer Mediated by Inhibition of Epithelial-to-Mesenchymal Transition Cancer Res., May 1, 2009; 69(9): 3779 - 3787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Kuzmanov, N. Jiang, C. R. Smith, A. Soosaipillai, and E. P. Diamandis Differential N-glycosylation of Kallikrein 6 Derived from Ovarian Cancer Cells or the Central Nervous System Mol. Cell. Proteomics, April 1, 2009; 8(4): 791 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Li, D. M. Danilenko, S. Bunting, R. Ganesan, S. Sa, R. Ferrando, T. D. Wu, G. A. Kolumam, W. Ouyang, and D. Kirchhofer The Serine Protease Marapsin Is Expressed in Stratified Squamous Epithelia and Is Up-regulated in the Hyperproliferative Epidermis of Psoriasis and Regenerating Wounds J. Biol. Chem., January 2, 2009; 284(1): 218 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Emami and E. P. Diamandis Utility of Kallikrein-Related Peptidases (KLKs) as Cancer Biomarkers Clin. Chem., October 1, 2008; 54(10): 1600 - 1607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Prassas, M. Paliouras, A. Datti, and E. P. Diamandis High-Throughput Screening Identifies Cardiac Glycosides as Potent Inhibitors of Human Tissue Kallikrein Expression: Implications for Cancer Therapies Clin. Cancer Res., September 15, 2008; 14(18): 5778 - 5784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Emami, D. Deperthes, J. Malm, and E. P. Diamandis Major Role of Human KLK14 in Seminal Clot Liquefaction J. Biol. Chem., July 11, 2008; 283(28): 19561 - 19569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Planque, L. Li, Y. Zheng, A. Soosaipillai, K. Reckamp, D. Chia, E. P. Diamandis, and L. Goodglick A Multiparametric Serum Kallikrein Panel for Diagnosis of Non-Small Cell Lung Carcinoma Clin. Cancer Res., March 1, 2008; 14(5): 1355 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Emami and E. P. Diamandis Human Kallikrein-related Peptidase 14 (KLK14) Is a New Activator Component of the KLK Proteolytic Cascade: POSSIBLE FUNCTION IN SEMINAL PLASMA AND SKIN J. Biol. Chem., February 8, 2008; 283(6): 3031 - 3041. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
